WuXiPRA, an independent CRO jointly owned by WuXi Pharmatec and PRA Health Sciences contribute clinical and regulatory experience to the joint venture from its China-based clinical organization. The organization covers all regions of the country and has employees working in 16 Chinese cities, with offices in Shanghai, Beijing, Wuhan, Guangzhou and Hong Kong. WuXi Pharmatec supplies laboratory services to the joint venture through a preferred provider arrangement. PRAHS offers the venture a wealth of global resources and clinical research expertise, reflected in more than 3,100 studies conducted over the last five years and contributions to 40 approved drugs in several therapeutic areas. PRAHS will also support the venture with its China-based staff and global technology capabilities, encompassing data capture, trial management and other IT systems.